Glutamine for the treatment of vincristine-induced neuropathy in children and adolescents with cancer

Children receiving glutamine had significantly improved sensory neuropathy scores compared to placebo on the NCI-CTCv3, with the glutamine group having 3.48 times higher odds of a drop in sensory neur

Effect: improvement; OR 3.48 (glutamine group had 3.48 times higher odds of sensory neuropathy score reduction)

Glutamine supplementation did not produce significant improvements in motor neuropathy scores by NCI-CTCv3 clinical assessment or by serial neuropsychological battery testing at any time point post-ra

Effect: null

Children in the glutamine group scored 8.42 points higher than the placebo group on the PedsQL 4.0 total quality of life summary score at time 3, reflecting self-reported improvement in overall qualit

Effect: improvement; 8.42 points higher on PedsQL total score

Glutamine was well tolerated with only mild side effects in 2% of patients, compliance was 82.5% of prescribed doses, and no significant difference in adverse effects was observed compared to placebo.

Effect: improvement

Analysis of serum glutamine, NGF, and VEGF at each designated time point did not reveal significant associations between candidate serum biomarkers and the development of VIPN, suggesting the effect o

Effect: null